| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain …
Over the last 12 months, insiders at Kazia Therapeutics Ltd ADR have bought $0 and sold $0 worth of Kazia Therapeutics Ltd ADR stock.
On average, over the past 5 years, insiders at Kazia Therapeutics Ltd ADR have bought $0 and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 4,531,633 shares for transaction amount of $5.26M was made by AUSTIN JOSIAH T (10 percent owner) on 2008‑07‑29.
| 2008-07-29 | AUSTIN JOSIAH T | 10 percent owner | 4.53M 14.6697% | $1.16 | $5.26M | -49.34% | ||
| 2006-09-01 | AUSTIN JOSIAH T | 10 percent owner | 6,000 0.1478% | $9.95 | $59,700 | +2.18% |
| Increased Positions | 14 | +100% | 2M | +1,545.84% |
| Decreased Positions | 5 | -35.71% | 122,179 | -77.29% |
| New Positions | 12 | New | 2M | New |
| Sold Out Positions | <1 | Sold Out | 52 | Sold Out |
| Total Postitions | 23 | +64.29% | 2M | +1,468.55% |
| Dauntless Investment Group, Llc | $591.00 | <0.01% | 118,139 | +2,370 | +2.05% | 2025-09-30 |
| Barclays Plc | $120.00 | 0% | 24,000 | 0 | 0% | 2025-09-30 |
| Rockefeller Capital Management L.P. | $54.00 | 0% | 10,700 | +10,700 | New | 2025-09-30 |
| Ubs Group Ag | $18.00 | 0% | 3,543 | +514 | +16.97% | 2025-09-30 |
| Citigroup Inc | $3.00 | 0% | 639 | +639 | New | 2025-09-30 |
| Rhumbline Advisers | $3.00 | 0% | 591 | 0 | 0% | 2025-09-30 |
| Morgan Stanley | $1.00 | 0% | 200 | +200 | New | 2025-09-30 |
| Arax Advisory Partners | $1.00 | 0% | 200 | 0 | 0% | 2025-09-30 |
| Mai Capital Management | $0 | 0% | 52 | 0 | 0% | 2025-09-30 |
| Osaic Holdings, Inc. | $0 | 0% | 10 | 0 | 0% | 2025-09-30 |